• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Januvia Patent expiry is February 2, 2019

Quote

anonymous

Guest
Why are we being lied to that the patent doesn’t run out until 2022? The patent for IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN. Soon after that will be generics. Definitely going to start looking. Not going to let this place blindside me.
 




After Januvia goes off patent all that is really left is Keytruda. When that goes off patent the Merck will be forced to shut its doors. This company has a garbage track record of bringing great products to market since Januvia. KEYTRUDA was absolute luck. That product was on a shelf, forgotten about. Then the genius scientists at Merck saw that BMS was having success with their PD1. Time to dust off the product discovered by Organon, and further developed by Schering. But Merck takes all the bows with how great their R&D is. Terrible joke!!
 








anonymous said:
After Januvia goes off patent all that is really left is Keytruda. When that goes off patent the Merck will be forced to shut its doors. This company has a garbage track record of bringing great products to market since Januvia. KEYTRUDA was absolute luck. That product was on a shelf, forgotten about. Then the genius scientists at Merck saw that BMS was having success with their PD1. Time to dust off the product discovered by Organon, and further developed by Schering. But Merck takes all the bows with how great their R&D is. Terrible joke!!
Click to expand...

I thought you were full of shit but I found out you are spot on. They almost left the last Hope for growth in our company on a shelf. The R&D here is third rate at best
 




anonymous said:
After Januvia goes off patent all that is really left is Keytruda. When that goes off patent the Merck will be forced to shut its doors. This company has a garbage track record of bringing great products to market since Januvia. KEYTRUDA was absolute luck. That product was on a shelf, forgotten about. Then the genius scientists at Merck saw that BMS was having success with their PD1. Time to dust off the product discovered by Organon, and further developed by Schering. But Merck takes all the bows with how great their R&D is. Terrible joke!!
Click to expand...

"Merck will be forced to shut its doors." LOL!! Merck has more money that God and will never be forced to end...As long as their are poison potions to concoct, willing guinea pigs to ingest them and get jabbed, and payors to fleece, Merck will thrive until the end of time...
 








anonymous said:
"Merck will be forced to shut its doors." LOL!! Merck has more money that God and will never be forced to end...As long as their are poison potions to concoct, willing guinea pigs to ingest them and get jabbed, and payors to fleece, Merck will thrive until the end of time...
Click to expand...

GM said the same thing in the 80s.
 








Its a litigious issue with Januvia having to do with the salts patented with Januvia. From a legal perspective a generic could be launched in 2019. It would not be identical due to the fillers but Sun Pharma (India) has every intention of launching this in 2019. MC will substitute the generic version.
 




anonymous said:
"Merck will be forced to shut its doors." LOL!! Merck has more money that God and will never be forced to end...As long as their are poison potions to concoct, willing guinea pigs to ingest them and get jabbed, and payors to fleece, Merck will thrive until the end of time...
Click to expand...

When sales start declining because of patent expiries and better competition, the stock will plummet. We are overvalued right now. Ken looks like a hero right now but it is a facade. Keytruda is not enough to keep investors happy when the revenue from all of the other products slows considerably. Januvia sales are very important, and we aren’t meeting expectations with it. The new Steglashit is garbage. Our sleep agent was asleep at launch, and continues to be unimpressive. Vaccines sales are not sustainable long term. Zostavax crashed and burned with the launch of Shingrix. Pneumovax is losing a lot of business to Prevnar for 19-64 year olds. There are always shortages with Hep B and several other vaccines. Gardasil is doing well, but is not enough.

Ken will be leaving soon with a lot of money and a big smile. Merck does have a lot of money but will not be able to sustain this structure long term. We will have to get much leaner and make strategic acquisitions in oncology.
 




anonymous said:
When sales start declining because of patent expiries and better competition, the stock will plummet. We are overvalued right now. Ken looks like a hero right now but it is a facade. Keytruda is not enough to keep investors happy when the revenue from all of the other products slows considerably. Januvia sales are very important, and we aren’t meeting expectations with it. The new Steglashit is garbage. Our sleep agent was asleep at launch, and continues to be unimpressive. Vaccines sales are not sustainable long term. Zostavax crashed and burned with the launch of Shingrix. Pneumovax is losing a lot of business to Prevnar for 19-64 year olds. There are always shortages with Hep B and several other vaccines. Gardasil is doing well, but is not enough.

Ken will be leaving soon with a lot of money and a big smile. Merck does have a lot of money but will not be able to sustain this structure long term. We will have to get much leaner and make strategic acquisitions in oncology.
Click to expand...

Excellent and factual assessment...you sound like you actually know what you are talking about and are really smart...

You know people that are smart and tell it like it is have no business at Merck right?

Mediocrity is the name of the game here...
 








anonymous said:
Its a litigious issue with Januvia having to do with the salts patented with Januvia. From a legal perspective a generic could be launched in 2019. It would not be identical due to the fillers but Sun Pharma (India) has every intention of launching this in 2019. MC will substitute the generic version.
Click to expand...
My husband is on Januvia, and because its cost is now $460 every 30 days (Silverscript), I've been researching internationally. Canada sells it for $159/30. But India has it for $59/42. Maybe they already have it available.
 








anonymous said:
My husband is on Januvia, and because its cost is now $460 every 30 days (Silverscript), I've been researching internationally. Canada sells it for $159/30. But India has it for $59/42. Maybe they already have it available.
Click to expand...
Nothing is free bitch get off your
Cheap ass I won't buy it for you probably if he lost 150 pounds he would be fine. I can just imagine the breadth of you ass!
 












anonymous said:
Nothing is free bitch get off your
Cheap ass I won't buy it for you probably if he lost 150 pounds he would be fine. I can just imagine the breadth of you ass!
Click to expand...
Sorry asswipe, my husband's family has a history of diabetes...and he is in pretty good shape, 6', 190 lbs. Have you ever heard of adult onset Type 2 Diabetes? Uh huh, I thought not. You just sit at your POA's grinding away thinking you're gonna tap whatever is available. What a joke.

I bet your Mother is very proud of you.

Most folks on Medicare/Social Security cannot afford Januvia.
 




anonymous said:
Sorry asswipe, my husband's family has a history of diabetes...and he is in pretty good shape, 6', 190 lbs. Have you ever heard of adult onset Type 2 Diabetes? Uh huh, I thought not. You just sit at your POA's grinding away thinking you're gonna tap whatever is available. What a joke.

I bet your Mother is very proud of you.

Most folks on Medicare/Social Security cannot afford Januvia.
Click to expand...
Get a job and leave the workers out of your whining. If you can't buy our product get another compound there are many out there!
 








Top Bottom
Back
Quote